Phaseline

Companies › Acrotech Biopharma

Acrotech Biopharma: clinical trials, targets and expected readouts

2 active drug programs in 13 registered trials: 8 Phase 1, 3 Phase 2, 2 Phase 3; Oncology; next expected readout Feb 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Pralatrexate
Dihydrofolate reductase inhibitor
DHFRPhase 3Peripheral T Cell Lymphoma; Advanced Solid Tumors; Lymphoma, T-Cell; PTCL …Feb 2027
Belinostat
Histone deacetylase inhibitor
HDAC (class I/II)Phase 3Peripheral T Cell Lymphoma; Locally Advanced Unresectable Primary Central Chondrosarcoma; Carcinoma, Neuroendocrine; Metastatic Uveal Melanoma …Jul 2030

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT03161223PralatrexatePhase 1Lymphoma, T-CellOncologyFeb 2023
NCT03240211PralatrexatePhase 1PTCLOncologyJul 2025
NCT04340843BelinostatPhase 2Locally Advanced Unresectable Primary Central ChondrosarcomaOncologyJan 2027
NCT07036133PralatrexatePhase 1Advanced Solid TumorsOncologyFeb 2027
NCT03598998PralatrexatePhase 1Anaplastic Large Cell LymphomaOncologyFeb 2027
NCT05627245BelinostatPhase 1Recurrent B-Cell Non-Hodgkin LymphomaOncologyJun 2027
NCT06406465BelinostatPhase 2Carcinoma, NeuroendocrineOncologyJul 2027
NCT05170334BelinostatPhase 2Metastatic Uveal MelanomaOncologyJan 2028
NCT07691450BelinostatPhase 1Recurrent Anaplastic Large Cell LymphomaOncologyNov 2029
NCT07691450PralatrexatePhase 1Recurrent Anaplastic Large Cell LymphomaOncologyNov 2029
NCT06072131BelinostatPhase 3Peripheral T Cell LymphomaOncologyJul 2030
NCT06072131PralatrexatePhase 3Peripheral T Cell LymphomaOncologyJul 2030
NCT07225985PralatrexatePhase 1Recurrent T-Cell Non-Hodgkin LymphomaOncologySep 2030

Targets

HDAC (class I/II) (1) DHFR (1)

Companies with the same targets

Xynomic Pharmaceuticals Jubilant Therapeutics Unravel Biosciences Great Novel Therapeutics Biotech & Medicals Italfarmaco Daiichi Sankyo Chengdu Zenitar Biomedical Technology Novelwise Pharmaceutical Chipscreen Biosciences Novartis

Companies built like this

Great Novel Therapeutics Biotech & Medicals Xynomic Pharmaceuticals Italfarmaco LaNova Medicines Zhejiang Quetzal Therapeutics

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.